Tyrer Cuzick Score
Description of test:
The Tyrer-Cuzick model is a risk assessment tool that uses the patient’s personal and family history information, as well as BRCA1/2 genetic testing status, to ascertain risk for developing breast cancer. Based on the patient’s Tyrer-Cuzick risk score, modified medical management may be indicated for the patient. A provider that orders any hereditary cancer genetic test that includes the BRCA1 and the BRCA2 genes can also order a Tyrer-Cuzick risk score calculation in conjunction. However, a Tyrer-Cuzick risk score cannot be ordered if a patient is male, is above 84 years old, has had a diagnosis of breast cancer, or has a personal or family history of a pathogenic/likely pathogenic variant in any of the following genes: ATM, CDH1, CHEK2, NBN, NF1, PALB2 ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, TP53 (if gene panel testing detects a likely pathogenic/pathogenic variants in these genes, the Tyrer-Cuzick risk score calculation will be canceled). A pathogenic/likely pathogenic variant in any of these genes already indicates a level of risk for developing breast cancer that meets requirements to trigger modified medical management. The BRCA1 and BRCA2 genes are not part of this exclusion criterion as the Tyrer-Cuzick risk model takes pathogenic/likely pathogenic variant in these genes into account and adjusts its calculation accordingly.
- Hereditary Cancer Requisition with a Sema4 Signal Hereditary Cancer test selected that includes BRCA1/2
- Tyrer-Cuzick Model Supplemental Order Form
- When ordered with a Sema4 Signal Hereditary Cancer test, results are reported to the referring physician within 10-14 business days (for STAT samples) and 3-4 weeks (for the non- STAT samples) from the receipt of the specimen.
- When ordered after a Sema4 Signal Hereditary Cancer test result has already been reported, results are reported within 3-5 business days from receipt of the test order.